VTRS

Malik Rajiv

Known title: PresidentCIK: 0001388111

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.

this person other insiders at VTRS

Transaction History

VTRS▲ Buy$0
VTRS▼ Sell$336K
VTRS▲ Buy$0
VTRS▼ Sell$45K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$3.2M
VTRS▲ Buy$0
VTRS▼ Sell$341K
VTRS▲ Buy$0
VTRS▼ Sell$31K
VTRS▼ Sell$1.6M
VTRS▼ Sell$707K
VTRS▼ Sell$600K
VTRS▼ Sell$595K
VTRS▼ Sell$1.2M
VTRS▼ Sell$1.2M
VTRS▼ Sell$1.2M
VTRS▼ Sell$2.7M
VTRS▼ Sell$901K
VTRS▲ Buy$0
VTRS▼ Sell$443K
VTRS▲ Buy$0
VTRS▼ Sell$39K
VTRS▲ Buy$0
VTRS▼ Sell$448K
VTRS▲ Buy$0
VTRS▼ Sell$22K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$2.0M
VTRS▲ Buy$0
VTRS▼ Sell$368K
VTRS▼ Sell$49K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$14K
VTRS▼ Sell$399K
VTRS▲ Buy$0
VTRS▼ Sell$255K
VTRS▼ Sell$26K
VTRS▼ Sell$325K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$955K
VTRS▲ Buy$0
VTRS▲ Buy$0
VTRS▼ Sell$153K
VTRS▲ Buy$0
VTRS▼ Sell$573K
VTRS▲ Buy$0
VTRS▼ Sell$240K
VTRS▲ Buy$0
VTRS▼ Sell$306K
VTRS▲ Buy$0
VTRS▼ Sell$7K

We use analytics to understand how market-wall is used. No personal data is sold.